Democritus University Of Thrace
- Address
- lock Available on a paid plan
Hematology and Blood Disorders
At Democritus University Of Thrace in Alexandroupoli, the Hematology department is involved in research focused on Hemic and Lymphatic Diseases, especially Anemia Due to Lower-Risk Myelodysplastic Syndromes. The trials are designed to explore new treatment options and assess whether novel therapies can improve blood-related outcomes for patients with these chronic conditions.
- Evaluating a new therapy for lower-risk myelodysplastic syndromes
- Studying approaches that may improve anemia and transfusion-related outcomes
This area of research reflects a strong interest in better managing blood disorders and improving quality of care for patients with limited treatment options.
Respiratory and Viral Infections
Clinical research at this site also includes Respiratory Tract Diseases and Virus Diseases, with a focus on COVID-19 in hospitalized adults. These studies aim to test whether new antiviral strategies can improve recovery and clinical outcomes when added to standard care.
- Assessing treatment effectiveness for hospitalized patients with COVID-19
- Testing a potential therapy for acute respiratory infections
The work supports broader efforts to strengthen care for viral respiratory illnesses and to identify better options for patients with serious infections.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Democritus University Of Thrace
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE) - Shionogi Protease Inhibitor (S-217622) | University Of Minnesota | Phase III | Not Recruiting | Jul 2023 | Oct 2025 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (6E)-6-[(6-Chloro-2-Methyl-2H-Indazol-5-Yl)Imino]-3-[(1-Methyl-1H-1,2,4-Triazol-3-Yl)Methyl]-1-[(2,4,5-Trifluorophenyl)Methyl]-1,3,5-Triazinane-2,4-Dione | 1 | Unknown | 2023-07-31 | 2023-07-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.